MedTrace Logo

Effectiveness of a Combined Group-individual Schema Therapy for Borderline Personality Disorder

NCT04211688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-12-26

No results posted yet for this study

Summary

Background and Objectives: Schema therapy has been shown to be of benefit in treating borderline personality disorder. However, it is still unclear what the most suitable treatment implementation format is and to what extent therapeutic gains may be generalizable to regular healthcare settings with limited resources.

Methods: A pragmatic randomized controlled trial was conducted ona representative Spanish sample of outpatients with a DSM-5 main diagnosis of borderline personality disorder. Patients were allocated either to a combined (group plus individual) schema therapy format (n=40) or to a group-only schema therapy format (n=40). Borderline personality disorder severity was the primary outcome, with other clinical variables considered as secondary outcomes (e.g., early maladaptive schemas, functioning). The assessment protocol included baseline, post-treatment (after 12months of treatment), and six-month follow-up evaluations. Data was analyzed through a two-way repeated measures ANOVA. Limitations were a limited follow-up assessment and the absence of multi-center data that detracted from the long-term stability and generalizability of the findings.

Conditions

  • Borderline Personality Disorder
  • Randomized Controlled Trial

Interventions

BEHAVIORAL

Group Schema therapy

Bimonthly outpatient psychotherapy delivered in individual setting

BEHAVIORAL

Individual Schema therapy

weekly outpatient psychotherapy delivered in group setting

Sponsors & Collaborators

  • Department of Health, Generalitat de Catalunya

    collaborator OTHER_GOV

  • Consorci Sanitari del Maresme

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-12
Primary Completion
2019-12-01
Completion
2019-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04211688 on ClinicalTrials.gov